Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 2 (2)

Trial Status

Active Not Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT06936566Phase 2Recruiting

MAGIC Ruxolitinib for aGVHD

NCT05090384Phase 2Active Not Recruiting

Pediatric GVHD Low Risk Steroid Taper Trial

Showing all 2 trials

Research Network

Activity Timeline